- Home
- VCYT
VCYT
Veracyte Inc.
as 04-25-2025 4:00pm EST
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | N/A | IPO Year: | 2013 |
| Target Price: | $41.78 | AVG Volume (30 days): | 974.6K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $19.09 - $47.32 | Next Earning Date: | 05-07-2025 |
| Revenue: | $445,764,000 | Revenue Growth: | 23.46% |
| Revenue Growth (this year): | 11.66% | Revenue Growth (next year): | 11.02% |
Stock Insider Trading Activity of Veracyte Inc. (VCYT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Leite John | VCYT | Chief Commercial Officer-CLIA | Mar 6 '25 | Sell | $31.50 | 7,411 | $234,629.55 | 105,260 | |
| Stapley Marc | VCYT | Chief Executive Officer | Mar 4 '25 | Sell | $33.70 | 52,697 | $1,756,855.23 | 268,035 | |
| McGuire Annie | VCYT | SVP, General Counsel | Mar 4 '25 | Sell | $33.69 | 1,142 | $38,476.49 | 70,308 | |
| Febbo Phillip G. | VCYT | Chief Scientific & Med Officer | Mar 4 '25 | Sell | $33.41 | 8,037 | $268,012.94 | 86,110 | |
| Leite John | VCYT | Chief Commercial Officer-CLIA | Feb 27 '25 | Sell | $33.84 | 5,746 | $194,444.64 | 105,260 | |
| Chambers Rebecca | VCYT | Chief Financial Officer | Feb 3 '25 | Sell | $43.85 | 527 | $23,108.95 | 113,510 |
Latest Veracyte Inc. News
VCYT Breaking Stock News: Dive into VCYT Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
Business Wire
4 days ago
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
Business Wire
5 days ago
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
Investor's Business Daily
9 days ago
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
Zacks
9 days ago
Should You Continue to Hold Veracyte Stock in Your Portfolio?
Business Wire
9 days ago
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
Zacks
11 days ago
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
Zacks
12 days ago
Here's Why Veracyte (VCYT) is a Strong Growth Stock
Compare VCYT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VCYT Veracyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.